Medicine recalls
|
| |
| Australia: Span-K (potassium chloride) 600 mg tablets: Recall for product correction - bottles supplied without child-resistant caps |
| |
The Therapeutic Goods Administration (TGA) advised consumers and health professionals that Aspen Pharmacare, in consultation with the TGA, has initiated a recall for product correction of Span-K (potassium chloride) 600 mg tablets.
Span-K 600 mg tablets are used to provide extra potassium for people who have lost potassium from their bodies because of illness or treatment with certain medicines. Span-K is also used for people who do not have enough potassium in their regular diet or cannot replace the potassium they have lost from their diet alone. Too much potassium can be harmful, so Span-K should only be taken if prescribed by a doctor.
It has been identified that bottles of this medicine have been supplied without child-resistant caps. There is no concern regarding the quality or safety of these medicines, other than the absence of child-resistant packaging.
To correct this issue, Aspen Australia has initiated a recall for product correction to replace all caps on bottles of Span-K 600 mg tablets, irrespective of batch number or expiry date. Consumers who are taking Span-K 600 mg tablets are advised to return the medicine to a pharmacy so that the cap can be replaced with one that is child-resistant.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/alert/span-k-potassium-chloride-600-mg-tablets
In Hong Kong, Span-K Tab 600mg (HK-36556) is a pharmaceutical product registered by Primal Chemical Co. Ltd. (Primal). The registered sales pack of the product is supplied in normal cap instead of child-resistant cap and so, the above Australia TGA recall announcement has no impact to Hong Kong.
Ends/Wednesday, April 19, 2017
Issued at HKT 15:00
|
| |
